A randomized clinical trial examining neural predictors of behavioral therapy outcomes for generalized anxiety disorder (GAD) has identified brain activity patterns that may indicate which treatment approaches will be most effective for individual patients, offering potential for personalized psychiatric care. The study conducted from 2016-2021 in Tulsa, Oklahoma, involved 56 treatment completers who underwent functional magnetic resonance imaging before beginning therapy and were then randomized to receive either behavioral activation (BA) or exposure therapy (EXP).
Common Predictors of Success
Researchers found that greater pre-treatment activation in the left dorsolateral prefrontal cortex (dlPFC) during negative affective outcomes predicted greater improvements in depression and anxiety symptoms across both treatment types. Additionally, greater pre-treatment behavioral avoidance during the approach-avoidance conflict task also predicted better outcomes across treatments. These findings were contrary to the researchers’ original hypothesis and suggest the dlPFC may play a crucial role in down-regulating negative affect among anxious individuals, assisting them in engaging with behavioral modification strategies that both therapies require.
Treatment-Specific Findings
Some differential predictors also emerged for specific treatment types. Lower levels of pre-treatment left amygdala activation to positive affective outcomes predicted favorable GAD symptom improvements in behavioral activation but showed limited improvements in exposure therapy, though this finding did not reach the study’s strict statistical threshold. This suggests that different neural profiles may respond preferentially to different therapeutic approaches, with implications for treatment selection.
Clinical Applications
The findings support a neuroscience-based approach to optimizing GAD treatment and may have transdiagnostic applications for anxiety and mood disorders more broadly. Participants received 10 manualized sessions of their assigned treatment while researchers tracked symptom changes over the course of therapy. The researchers note that larger longitudinal studies in clinical settings are needed to validate these findings and determine their potential for personalizing treatment recommendations based on individual brain activity patterns, particularly in routine clinical practice settings.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.nature.com/articles/s41398-025-03460-x